-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Fmoc-Gly-OH-[13C2,15N]
Category | Influenza Virus |
CAS | 285978-13-4 |
Description | Fmoc-Gly-OH-2-[13C2,15N] is the labelled analogue of Fmoc-Gly-OH. Fmoc-Gly-OH is an N-Fmoc-protected form of Glycine. Glycine is one of the non-essential amino acids for humans. Glycine is an inhibitory neurotransmitter in the central nervous system. |
Product Information
Synonyms | N-(9-Fluorenylmethoxycarbonyl)-glycine-2-13C,15N,Glycine-2-13C,15N N-Fmoc; DTXSID90583953; ACM285978134; N-{[(9H-Fluoren-9-yl)methoxy]carbonyl}(13C2,15N)glycine; N-(9-Fluorenylmethoxycarbonyl)-glycine-13C2,15N, Glycine-13C2,15N, N-Fmoc |
IUPAC Name | (((9H-fluoren-9-yl)methoxy)carbonyl)glycine-13C2-15N |
Molecular Weight | 300.28 |
Molecular Formula | C15[13C]2H15[15N]O4 |
Canonical SMILES | C1=CC=C2C(=C1)C(C3=CC=CC=C32)COC(=O)NCC(=O)O |
InChI | InChI=1S/C17H15NO4/c19-16(20)9-18-17(21)22-10-15-13-7-3-1-5-11(13)12-6-2-4-8-14(12)15/h1-8,15H,9-10H2,(H,18,21)(H,19,20)/i9+1,16+1,18+1 |
InChIKey | NDKDFTQNXLHCGO-PHHLUUBBSA-N |
Melting Point | 174-175 °C |
Purity | 99% atom 13C; 98% atom 15N |
Solubility | In vitro: 10 mM in DMSO |
Appearance | Solid powder |
Storage | 2-8 °C |
In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs. |
PSA | 79.12000 |
Target | Influenza Virus; Bacterial |